支气管哮喘靶向治疗的研究进展  

Research progress of targeted therapy for bronchial asthma

作　　者：朱桂萍 叶伶[1] 金美玲[1] Zhu Guiping;Ye Ling;Jin Meiling(Department of Respiratory and Critical Care Medicine,Zhongshan Hospital of Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院呼吸与危重症医学科,上海200032

出　　处：《国际呼吸杂志》2021年第7期529-535,共7页International Journal of Respiration

基　　金：国家重点研发计划(2016YFC1304000、2016YFC1304002);上海市重中之重临床医学中心和重点学科建设计划(2017ZZ02013)。

摘　　要：支气管哮喘(哮喘)是一种常见的具有异质性的慢性气道炎症性疾病。尽管已有包括吸入糖皮质激素在内的很多治疗方法,仍有许多哮喘患者未得到有效控制。据研究,很多炎症介质参与了哮喘的发病过程。目前已研发出多种针对炎症介质的单克隆抗体和小分子化学合成药物用于治疗哮喘,由此哮喘迈入靶向治疗的时代。本文对哮喘靶向治疗的进展及可能的新靶点进行综述,从而为患者提供更加个体化的治疗。Bronchial asthma(asthma)is a common chronic airway inflammatory disease with heterogeneity.Although various treatments are available,including inhaled corticosteroids,many asthmatics are still not well controlled.According to studies,many inflammatory mediators are involved in the pathogenesis of asthma which result in a variety of monoclonal antibodies and small-molecule chemotherapeutic drugs targeting the inflammatory mediators being developed for the treatment of asthma.Thus,treatment of asthma enters the era of targeted therapy.This review discusses the progress of targeted therapy in asthma and possible new targets so as to provide more individualized therapy for patients.

关 键 词：哮喘 炎症介质 靶向治疗 

分 类 号：R562.25[医药卫生—呼吸系统]